高效CIK和贝伐单抗联合化疗治疗晚期恶性肿瘤的护理

Nursing of chemotherapy of combined CIK with bevacizumab on terminal malignant tumor

目的探讨高效CIK和贝伐单抗联合化疗治疗晚期恶性肿瘤的护理措施，以期减少不良反应，提高临床疗效。方法回顾性分析高效CIK和贝伐单抗联合化疗治疗40例晚期恶性肿瘤的护理方法及效果。结果所有肿瘤患者均未因高效CIK和贝伐单抗引起的严重不良反应而终止治疗。3例患者出现发热，2例轻微过敏，9例高血压，2例尿蛋白阳性，5例口腔出血，1例少量咳血，均及时对症治疗护理，顺利完成治疗计划。结论根据高效CIK和贝伐单抗的治疗特点，恰当制定护理措施可有效预防和减轻各种不良反应的发生，从而提高疗效。

Objective To investigate the efficient care for the terminal malignant tumor therapy with CIK and bevacizumab, so as to reduce the adverse reactions and improve clinical outcomes. Methods A retrospectiveanalysis on care methods and effects was conducted in 40 patients with terminal malignant tumor received CIK and bevacizumab chemotherapy. Results No patients was terminate therapy for serious adverse reactions of CIK and bevacizumab, and 3 cases of fever, 2 cases of mild allergy, 9 cases of hypertension, 2 cases of urinary protein, 5 cases of oral bleeding, 1 case with scant hemoptysis , they were successfully finish the treatment plan after timely treated. Conclusions Appropriately formulating nursing interventions according to the treatment characteristics of CIK and bevacizumab can effectively prevent and mitigate the adverse reactions, and imnrove the efficacy.